Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

Elite’s CNS stimulants
1.) Adderall IR- approved -launched - IQVIA $400 Million market
2.)Adderall XR -approved -launched- IQVIA $1.914 Billion market
3.)Undisclosed Godzilla IQVIA $2.176 Billion market ER combination CNS stimulant 100% owned by Elite

Actual IQVIA $4.0 Billion plus combined markets

Look at top of this list of shortages



Elite’s three CNS drugs have the biggest delta (the biggest difference between the demand which outstrips the supply). Ergo, there is a SHORTAGE of CNS drugs. This means Elite's IR and XR Adderall should increase in sales and the FDA snd DEA should be cognizant of the need to fill the demand.

: "We would like to thank the good folks at IQVIA for providing the data."